📊 FDMT Key Takeaways
Is 4D Molecular Therapeutics, Inc. (FDMT) a Good Investment?
4D Molecular Therapeutics is a pre-revenue biotech company with severe operational losses consuming ~$109M in annual operating cash flow against only $85.2M in revenue, indicating the revenue is insufficient to cover core operations. The company is burning cash rapidly with negative free cash flow of -$109.6M annually, which will deplete the current $60.2M cash position within months without significant changes. While the balance sheet shows reasonable equity backing, the fundamental business model is unsustainable at current burn rates without substantial revenue growth or capital raises.
4D Molecular Therapeutics shows very weak operating fundamentals, with deeply negative operating and net margins, substantial annual cash burn, and no evidence of improving revenue momentum in the latest period. The balance sheet is currently supported by high liquidity, no long-term debt, and a large equity base, but the business remains dependent on external funding or future clinical/commercial execution to offset persistent losses.
Why Buy 4D Molecular Therapeutics, Inc. Stock? FDMT Key Strengths
- Strong balance sheet with $505.7M stockholders equity and minimal debt ($0 long-term debt)
- Excellent liquidity position with 9.39x current and quick ratios indicating short-term solvency
- Diversified asset base of $566.7M providing runway for operations
- Strong near-term liquidity with 9.39x current and quick ratios
- Debt-free capital structure with 0.00x debt-to-equity
- Large equity base relative to liabilities, providing balance sheet flexibility
FDMT Stock Risks: 4D Molecular Therapeutics, Inc. Investment Risks
- Severe cash burn of $109.6M annually with only $60.2M cash available; runway exhausted in ~6-7 months
- Operating losses of $159.5M with negative operating margin of -187.2% indicating revenue cannot cover core costs
- Revenue base of $85.2M insufficient to support current operational expense structure; company heavily dependent on R&D spending without commercial validation
- Severely negative profitability, including -187.2% operating margin and -164.4% net margin
- Sustained negative free cash flow of about $109.62M indicates ongoing cash consumption
- Flat revenue growth suggests weak current growth quality and limited operating leverage
Key Metrics to Watch
- Operating cash flow trend and path to breakeven cash burn
- Revenue growth rate and pipeline advancement toward commercialization milestones
- Cash runway depletion rate and necessity for capital raises or major cost restructuring
- Quarterly operating cash burn relative to cash and short-term liquidity
- Revenue durability and any improvement in operating loss trend
4D Molecular Therapeutics, Inc. (FDMT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.39x current ratio provides a solid financial cushion.
FDMT Profit Margin, ROE & Profitability Analysis
FDMT vs Healthcare Sector: How 4D Molecular Therapeutics, Inc. Compares
How 4D Molecular Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is 4D Molecular Therapeutics, Inc. Stock Overvalued? FDMT Valuation Analysis 2026
Based on fundamental analysis, 4D Molecular Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
4D Molecular Therapeutics, Inc. Balance Sheet: FDMT Debt, Cash & Liquidity
FDMT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: 4D Molecular Therapeutics, Inc.'s revenue has grown significantly by 372% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.98 indicates the company is currently unprofitable.
FDMT Revenue Growth, EPS Growth & YoY Performance
FDMT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.0K | -$32.4M | $-0.79 |
| Q2 2025 | $5.0K | -$32.4M | $-0.63 |
| Q1 2025 | $14.0K | -$32.4M | $-0.66 |
| Q3 2024 | $3.0K | -$10.3M | $-0.24 |
| Q2 2024 | $5.0K | -$28.7M | $-0.63 |
| Q1 2024 | $28.0K | -$28.7M | $-0.66 |
| Q3 2023 | $500.0K | -$10.3M | $-0.24 |
| Q2 2023 | $162.0K | -$26.3M | $-0.77 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
4D Molecular Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
FDMT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for 4D Molecular Therapeutics, Inc. (CIK: 0001650648)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FDMT
What is the AI rating for FDMT?
4D Molecular Therapeutics, Inc. (FDMT) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 85% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are FDMT's key strengths?
Claude: Strong balance sheet with $505.7M stockholders equity and minimal debt ($0 long-term debt). Excellent liquidity position with 9.39x current and quick ratios indicating short-term solvency. ChatGPT: Strong near-term liquidity with 9.39x current and quick ratios. Debt-free capital structure with 0.00x debt-to-equity.
What are the risks of investing in FDMT?
Claude: Severe cash burn of $109.6M annually with only $60.2M cash available; runway exhausted in ~6-7 months. Operating losses of $159.5M with negative operating margin of -187.2% indicating revenue cannot cover core costs. ChatGPT: Severely negative profitability, including -187.2% operating margin and -164.4% net margin. Sustained negative free cash flow of about $109.62M indicates ongoing cash consumption.
What is FDMT's revenue and growth?
4D Molecular Therapeutics, Inc. reported revenue of $85.2M.
Does FDMT pay dividends?
4D Molecular Therapeutics, Inc. does not currently pay dividends.
Where can I find FDMT SEC filings?
Official SEC filings for 4D Molecular Therapeutics, Inc. (CIK: 0001650648) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FDMT's EPS?
4D Molecular Therapeutics, Inc. has a diluted EPS of $-2.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FDMT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, 4D Molecular Therapeutics, Inc. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FDMT stock overvalued or undervalued?
Valuation metrics for FDMT: ROE of -27.7% (sector avg: 15%), net margin of -164.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FDMT stock in 2026?
Our dual AI analysis gives 4D Molecular Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FDMT's free cash flow?
4D Molecular Therapeutics, Inc.'s operating cash flow is $-109.1M, with capital expenditures of $536.0K. FCF margin is -128.6%.
How does FDMT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -164.4% (avg: 12%), ROE -27.7% (avg: 15%), current ratio 9.39 (avg: 2).